Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
About
The purpose of this FOA is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.
The Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) is a federal funding opportunity designed to support researchers and organizations in planning rigorous clinical trials across the cancer prevention and control spectrum. This grant addresses a critical gap in cancer research by providing resources to conduct preparatory studies that fill information gaps before full-scale trial implementation. Applicants can use funding to investigate study population characteristics, assess accrual feasibility, evaluate intervention protocols, identify outcome measures, address statistical challenges, and test operational feasibility. This program is ideal for researchers who have identified a promising cancer prevention or control intervention but need preliminary data and evidence to design a robust clinical trial. Eligible applicants include academic institutions, federal agencies, community-based organizations, faith-based organizations, HBCUs, Hispanic-serving institutions, and tribal governments. By securing this planning grant, researchers can reduce protocol changes, minimize unnecessary expenses, and accelerate the path to launching well-designed clinical trials that improve cancer prevention, screening, early detection, treatment outcomes, and survivor care. The deadline for applications is October 25, 2027.
Funding Facts
● Applications openDeadline
October 25, 2027
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Amount varies by cycle
Deadline
2027-10-25
Grant Type
federal
Application Cycle
Annual (Deadline: October 25, 2027)
Best For
Academic institutions, HBCUs, Hispanic-serving institutions, tribal governments, community-based organizations, and faith-based organizations planning cancer prevention and control clinical trials
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Govern
Frequently Asked Questions
Who is eligible for Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)?
Eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible federal agencies, faith-based and community-based organizations, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), and Indian/Native American Tribal Governments. For comprehensive eligibility details and institutional classifications, applicants should consult the official NIH/NCI website.
How much funding does Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) provide?
Specific funding amounts are not specified in the available information. Grant amounts may vary by cycle and application scope. Applicants should review the official NCI Funding Opportunity Announcement (FOA) for current funding details and budget guidelines.
How do I apply for Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)?
Applications are typically submitted through Grants.gov or the NIH eRA Commons system. You will need to prepare a grant proposal outlining your preparatory study design, research objectives, budget, and institutional support. The next application deadline is October 25, 2027. Visit the official NCI website or Grants.gov for detailed application instructions, required forms, and submission guidelines.
What can Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional) funding be used for?
Funding supports preparatory studies and planning activities for clinical trials in cancer prevention and control, including: investigating study population characteristics, assessing recruitment and accrual feasibility, evaluating intervention approaches, identifying appropriate outcomes and endpoints, addressing data and statistical challenges, testing new trial designs, and evaluating operational feasibility. These planning activities help researchers close information gaps and refine trial protocols before full-scale implementation.
Last updated: July 5, 2026